










A

+DENV-I

	Mock	MLN-2238	Carfilzomib	Bortezomib
DAPI DENV-E				
	DMSO	Delanzomib	Oprozomib	MG-115
				

B

Treatment	Percentage of DENV-E positive cells (%)
Mock	0
DMSO	~26
MLN-2238	0
Carfilzomib	0
Bortezomib	0
Delanzomib	0
Oprozomib	0
MG-115	0